Kelvin is currently Director of Portfolio Management at Novartis in Basel, Switzerland, where he is responsible for evaluating project and portfolio investment decisions to support the company’s global drug development pipeline. He is a globally recognized and respected thought leader in biopharma innovation and R&D productivity, with over 20 years of experience in various roles across big pharma (Novartis, Merck Serono), biotech start-ups (Senexis), management consulting (McKinsey, PwC, Quantelium) and venture capital (Inventages). A firm believer in the importance and need for unconventional critical strategic thinking to challenge and disrupt the status quo, he lives by the entrepreneurial spirit and motto to “aim high, think big and different, start small, fail cheap and learn fast”. Kelvin holds a PhD in protein engineering from Trinity College at the University of Cambridge, and was also a Research Fellow at Peterhouse.
GapSummit is the premier, global, intergenerational biotechnology summit that attracts world leaders and the next generation of leaders to substantively discuss pressing challenges facing the bioeconomy and catalyze innovation to address these challenges.
GBR is a not-for-profit that connects biotech think-tanks, industrial leaders and research pioneers to young bio-leaders of tomorrow. GBR is solely led by young passionate and engaged researchers, students and professionals from across the world. GapSummit is GBR’s flagship event to advance its mission of developing and inspiring the next generation of leaders in the global bio-economy.